New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
09:04 EDTBTXBioTime raises $6.4M in equity financing
BioTime announced that on May 1, the company received approximately $6.4M in equity financing. The funds were raised from current long-term investors in the company and will be used for funding product development, including this year's anticipated pivotal Renevia clinical trial, as well as other general operating expenses.
News For BTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
12:01 EDTBTXBioTime unit, GE Healthcare sign set of license agreements, terms not disclosed
BioTime (BTX) announced that its subsidiary ES Cell International Pte. Ltd. and GE Healthcare (GE) have signed a set of license agreements through which GEHC received rights to ESI’s stem cell patents and ESI received rights to stem cell patents controlled by GEHC, in both cases for the development of cellular assays and models derived from stem cells for use in drug discovery and toxicity screening. In addition, the agreements give GEHC the right to grant sub-licenses to the ESI patent portfolio and, in certain circumstances, ESI may further sublicense its rights for the purpose of marketing stem cell-derived products. Financial terms were not disclosed.
11:01 EDTBTXBioTime completes initial enrollment of urine-based bladder cancer test trial
BioTime and its subsidiary OncoCyte Corporation announced that OncoCyte has completed enrollment in the initial clinical study of its urine-based bladder cancer diagnostic test. The study, which involved 100 patients, was conducted in collaboration with investigators in the Department of Pathology, Division of Cytopathology, at a leading medical institution with an international reputation for excellence and discovery. Initial results of the study have been submitted for presentation at a large upcoming cancer society meeting; eventual publication of the final results in a peer-reviewed clinical journal is also anticipated. The goal of this clinical study was to assess the performance of OncoCyte’s proprietary diagnostic technology in detecting the most common type of bladder cancer; namely, urothelial carcinoma. The ability of the markers tested in the studies to determine the absence, presence, or progression of UC in patients will determine the specific nature of the bladder cancer test to be developed and the regulatory approval pathway that OncoCyte will pursue.
December 12, 2014
14:52 EDTBTXBioTime to host investor and analyst meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use